

ERESEARCHTECHNOLOGY INC /DE/

Form 10-Q

May 05, 2005

[Click here to Cover](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the quarterly period ended March 31, 2005.

or

Transitional report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transitional period from _____ to _____

Commission file number 0-29100

eResearchTechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

22-3264604

(State or other jurisdiction of incorporation
or organization)

(I.R.S. Employer Identification No.)

30 South 17th Street
Philadelphia, PA

19103

(Address of principal executive offices)

(Zip Code)

215-972-0420

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year,
if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Edgar Filing: ERESEARCHTECHNOLOGY INC /DE/ - Form 10-Q

The number of shares of Common Stock, \$.01 par value, outstanding as of April 29, 2005, was 50,486,403.

Back to Cover

eResearchTechnology, Inc. and Subsidiaries

INDEX

| | <u>Page</u> |
|---|--------------|
| <u>Part</u> | |
| <u>I. Financial Information</u> | |
| <u>Item 1.</u> | |
| <u>Consolidated Financial Statements</u> | |
| <u>Consolidated Balance Sheets-December 31, 2004 and March 31, 2005 (unaudited)</u> | <u>3</u> |
| <u>Consolidated Statements of Operations (unaudited) Three Months Ended March 31, 2004 and 2005</u> | <u>4</u> |
| <u>Consolidated Statements of Cash Flows (unaudited) Three Months Ended March 31, 2004 and 2005</u> | <u>5</u> |
| <u>Notes to Consolidated Financial Statements (unaudited)</u> | <u>6-10</u> |
| <u>Item 2.</u> | |
| <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>11-19</u> |
| <u>Item 3.</u> | |
| <u>Quantitative and Qualitative Disclosures about Market Risk</u> | <u>19</u> |
| <u>Item 4.</u> | |
| <u>Controls and Procedures</u> | <u>20</u> |
| <u>Part</u> | |
| <u>II. Other Information</u> | |
| <u>Item 6.</u> | |
| <u>Exhibits</u> | <u>21</u> |
| <u>Signatures</u> | <u>22</u> |
| <u>Exhibit Index</u> | <u>23</u> |

[Back to Index](#)**Part 1. Financial Information****Item 1. Consolidated Financial Statements**

eResearchTechnology, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands of dollars, except per share amounts)

| | <u>December 31, 2004</u> | <u>March 31, 2005</u> |
|--|--------------------------|-----------------------|
| | | (unaudited) |
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 45,806 | \$ 38,877 |
| Short-term investments | 22,942 | 31,942 |
| Accounts receivable, net | 14,798 | 14,814 |
| Prepaid expenses and other | 3,522 | 3,831 |
| Deferred income taxes | 323 | 323 |
| | <hr/> | <hr/> |
| Total current assets | 87,391 | 89,787 |
| Property and equipment, net | 25,204 | 25,310 |
| Goodwill | 1,212 | 1,212 |
| Other assets | 782 | 498 |
| Deferred income taxes | 1,936 | 1,332 |
| | <hr/> | <hr/> |
| Total assets | \$ 116,525 | \$ 118,139 |
| | <hr/> | <hr/> |
| Liabilities and Stockholders Equity | | |
| Current Liabilities: | | |
| Accounts payable | \$ 2,455 | \$ 2,169 |
| Accrued expenses | 4,318 | 4,269 |
| Income taxes payable | 2,147 | 176 |
| Current portion of capital lease obligations | 233 | 167 |
| Deferred revenues | 20,325 | 19,614 |
| | <hr/> | <hr/> |
| Total current liabilities | 29,478 | 26,395 |
| | <hr/> | <hr/> |
| Capital lease obligations, excluding current portion | 193 | 159 |
| | <hr/> | <hr/> |
| Commitments and contingencies | | |
| Stockholders Equity: | | |
| Preferred stock - \$10.00 par value, 500,000 shares authorized, none issued and outstanding | | |
| Common stock - \$.01 par value, 175,000,000 shares authorized, 56,396,696 and 56,506,808 shares issued, respectively | 564 | 565 |
| Additional paid-in capital | 69,694 | 70,558 |
| Accumulated other comprehensive income | 1,601 | 1,395 |
| Retained earnings | 46,550 | 50,622 |
| Treasury stock, 6,067,519 shares at cost | (31,555) | (31,555) |
| | <hr/> | <hr/> |
| Total stockholders equity | 86,854 | 91,585 |
| | <hr/> | <hr/> |
| Total liabilities and stockholders equity | \$ 116,525 | \$ 118,139 |
| | <hr/> | <hr/> |

The accompanying notes are an integral part of these statements.

[Back to Index](#)

eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share amounts)
(unaudited)

| | Three Months Ended March 31, | |
|---|-------------------------------------|-------------|
| | 2004 | 2005 |
| Net revenues: | | |
| Licenses | \$ 2,453 | \$ 1,663 |
| Services | 18,010 | 15,902 |
| Site support | 5,629 | 5,349 |
| | 26,092 | 22,914 |
| Costs of revenues: | | |
| Cost of licenses | 122 | 133 |
| Cost of services | 5,985 | 6,490 |
| Cost of site support | 2,363 | 3,183 |
| | 8,470 | 9,806 |
| Gross margin | 17,622 | 13,108 |
| Operating expenses: | | |
| Selling and marketing | 2,453 | 2,338 |
| General and administrative | 2,150 | 2,896 |
| Research and development | 973 | 991 |
| | 5,576 | 6,225 |
| Operating income | 12,046 | 6,883 |
| Other income (expense), net | 108 | (5) |
| | 12,154 | 6,878 |
| Income before income taxes | 12,154 | 6,878 |
| Income tax provision | 4,886 | 2,806 |
| | 7,268 | 4,072 |
| Net income | \$ 7,268 | \$ 4,072 |
| Basic net income per share | \$ 0.14 | \$ 0.08 |
| Diluted net income per share | \$ 0.13 | \$ 0.08 |
| Shares used to calculate basic net income per share | 50,933 | 50,370 |
| Shares used to calculate diluted net income per share | 55,405 | 53,324 |

The accompanying notes are an integral part of these statements.

[Back to Index](#)

eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(In thousands of dollars)
(unaudited)

| | <u>Three Months Ended March 31,</u> | |
|---|-------------------------------------|------------------|
| | <u>2004</u> | <u>2005</u> |
| Operating activities: | | |
| Net income | \$ 7,268 | \$ 4,072 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 2,006 | 2,630 |
| Cost of sale of equipment | | 269 |
| Provision for uncollectible accounts | 39 | 45 |
| Stock option income tax benefits | 3,647 | 540 |
| Investment impairment charge | | 284 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (4,188) | (120) |
| Prepaid expenses and other | (995) | (238) |
| Accounts payable | (14) | (275) |
| Accrued expenses | (669) | (119) |
| Income taxes | 960 | (1,370) |
| Deferred revenues | 5,349 | (672) |
| Net cash provided by operating activities | <u>13,403</u> | <u>5,046</u> |
| Investing activities: | | |
| Purchases of property and equipment | (4,035) | (3,148) |
| Purchases of short-term investments | (10,900) | (15,175) |
| Proceeds from sales of short-term investments | 3,596 | 6,175 |
| Net cash used in investing activities | <u>(11,339)</u> | <u>(12,148)</u> |
| Financing activities: | | |
| Repayment of capital lease obligations | (161) | (100) |
| Proceeds from exercise of stock options | 867 | 326 |
| Net cash provided by financing activities | <u>706</u> | <u>226</u> |
| Effect of exchange rate changes on cash | 58 | (53) |
| Net increase (decrease) in cash and cash equivalents | 2,828 | (6,929) |
| Cash and cash equivalents, beginning of period | 38,364 | 45,806 |
| Cash and cash equivalents, end of period | <u>\$ 41,192</u> | <u>\$ 38,877</u> |

The accompanying notes are an integral part of these statements.

[Back to Index](#)

eResearchTechnology, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(unaudited)

Note 1. Basis of Presentation

The accompanying unaudited consolidated financial statements, which include the accounts of eResearchTechnology, Inc. (the Company or we) and its wholly owned subsidiaries, have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2005 are not necessarily indicative of the results that may be expected for the year ending December 31, 2005. Further information on potential factors that could affect our financial results can be found in our Report on Form 10-K for the year ended December 31, 2004 filed with the Securities and Exchange Commission and in this Form 10-Q.

Note 2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenues and expenses during the reporting period. Actual results could differ from those estimates.

Property and Equipment

Pursuant to Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use, we capitalize costs associated with internally developed and/or purchased software systems for new products and enhancements to existing products that have reached the application development stage and meet recoverability tests. These costs are included in property and equipment. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software, and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project.

Amortization of capitalized software development costs is charged to cost of revenues. Amortization of capitalized software development costs was \$581,000 and \$370,000 for the three months ended March 31, 2004 and 2005, respectively. For the three months ended March 31, 2004 and 2005, we capitalized \$452,000 and \$728,000, respectively, of software development costs related to labor and consulting, and \$1,139,000 and \$0, respectively, of software development costs related to direct costs of materials. As of March 31, 2005, \$4,162,000 of capitalized costs have not yet been placed in service and are therefore not being amortized.

Long-lived Assets

In accordance with the provisions of Statement of Financial Accounting Standards (SFAS) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, when events or circumstances so indicate, we assess the potential impairment of our long-lived assets based on anticipated undiscounted cash flows from the assets. Such events and circumstances include a sale of all or a significant part of the operations associated with the long-lived asset, or a significant decline in the operating performance of the asset. If an impairment is indicated, the amount of the impairment charge would

Back to Index

be calculated by comparing the anticipated discounted future cash flows to the carrying value of the long-lived asset. At March 31, 2005, no impairment was indicated.

Software Development Costs

Research and development expenditures are charged to operations as incurred. SFAS No. 86, *Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed*, requires the capitalization of certain software development costs subsequent to the establishment of technological feasibility. Since software development costs have not been significant after the establishment of technological feasibility, all such costs have been charged to expense as incurred.

Stock-Based Compensation

In December 2002, SFAS No. 148, *Accounting for Stock-Based Compensation Transition and Disclosure*, was issued. SFAS No. 148 amended SFAS No. 123, *Accounting for Stock-Based Compensation*, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amended the disclosure requirements of SFAS No. 123 related to the disclosures about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The disclosure provisions of SFAS No. 148 are applicable to interim or annual periods that end after December 15, 2002, and as such have been incorporated below.

SFAS No. 123, as amended by SFAS No. 148, permits companies to (i) recognize as expense the fair value of stock-based awards, or (ii) continue to apply the provisions of Accounting Principles Board (APB) Opinion No. 25, *Accounting for Stock Issued to Employees* and related interpretations, and provide pro forma net income and earnings per share disclosures for employee stock option grants as if the fair value based method defined in SFAS No. 123 had been applied. We continue to apply the provisions of APB Opinion No. 25 and provide the pro forma disclosures in accordance with the provisions of SFAS Nos. 123 and 148. Under APB Opinion No. 25, we have not recorded any stock-based employee compensation cost associated with our stock option plans, as all options granted under the plans had an exercise price equal to the market value of the underlying common stock on the date of grant.

The following table illustrates the effect on net income and earnings per share if we had applied the fair value recognition provisions of SFAS No. 123 to our stock option plans (in thousands, except per share amounts):

| | Three Months Ended March 31, | |
|--|-------------------------------------|-------------|
| | 2004 | 2005 |
| Net income, as reported | \$ 7,268 | \$ 4,072 |
| Deduct: Net stock-based employee compensation expense determined under fair value based method, net of related tax effects | (705) | (683) |
| Pro forma net income | \$ 6,563 | \$ 3,389 |
| Earnings per share: | | |
| Basic - as reported | \$ 0.14 | \$ 0.08 |
| Basic - pro forma | \$ 0.13 | \$ 0.07 |
| Diluted - as reported | \$ 0.13 | \$ 0.08 |
| Diluted - pro forma | \$ 0.12 | \$ 0.06 |

Pro forma net income reflects only options granted through March 31, 2005 and, therefore, may not be representative of the effect for future periods.

[Back to Index](#)**Stock Splits**

On May 27, 2004, we effected a 3-for-2 split of our common stock. All share and per share data have been restated to reflect this split of our common stock as if the stock split had occurred as of December 31, 2003.

Note 3. Net Income per Common Share

Basic net income per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the dilutive effect of common stock equivalents, which consist of stock options. The dilutive effect of stock options is calculated using the treasury stock method.

The tables below set forth the reconciliation of the numerators and denominators of the basic and diluted net income per share computations (in thousands, except per share amounts):

Three Months Ended March 31,

| 2004 | Net Income | Shares | Per Share Amount |
|---------------------------|---------------|--------|------------------------|
| Basic net income | \$ 7,268 | 50,933 | \$ 0.14 |
| Effect of dilutive shares | | 4,472 | (0.01) |
| Diluted net income | \$ 7,268 | 55,405 | \$ 0.13 |
| 2005 | | | |
| Basic net income | \$ 4,072 | 50,370 | \$ 0.08 |
| Effect of dilutive shares | | 2,954 | |
| Diluted net income | \$ 4,072 | 53,324 | \$ 0.08 |

In computing diluted net income per share, 598,800 and 1,192,000 options to purchase shares of common stock were excluded from the computations for the three months ended March 31, 2004 and 2005, respectively. These options were excluded from the computations because the exercise prices of such options were greater than the average market price of our common stock during the respective periods.

Note 4. Comprehensive Income

SFAS No. 130, Reporting Comprehensive Income, requires companies to classify items of other comprehensive income by their nature in the financial statements and display the accumulated balance of other comprehensive income separately from retained earnings and additional paid-in-capital in the stockholders' equity section of the balance sheet. Our comprehensive income includes net income and unrealized gains and losses from foreign currency translation as follows (in thousands):

| | Three Months Ended March 31, | |
|---------------------------------|------------------------------|----------|
| | 2004 | 2005 |
| Net income | \$ 7,268 | \$ 4,072 |
| Other comprehensive income: | | |
| Currency translation adjustment | 129 | (206) |
| Comprehensive income | \$ 7,397 | \$ 3,866 |

Back to Index

Note 5. Recent Pronouncements

In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123R, Share-Based Payment. SFAS No. 123R is a revision of SFAS No. 123. SFAS No. 123R establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. SFAS No. 123R requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees, but expresses no preference for a type of valuation model. In April 2005, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 107 which provided additional guidance in implementing SFAS No. 123R without modifying the conclusions or requirements of SFAS No. 123R. In April 2005, the SEC also deferred the effective date of SFAS No. 123R for many registrants, including our company. Whereas SFAS No. 123R originally was to be effective for most public companies' first interim period beginning after June 15, 2005, the deferral now requires the adoption to be effective for most public companies' first annual period beginning after June 15, 2005. We currently use the intrinsic value method to measure compensation expense for stock-based awards to our employees. Accordingly, we do not recognize any compensation expense related to stock option grants that we issue under our stock option plans. Under the new rules, we will be required to adopt a fair value based method for measuring the expense and this may materially impact our future reported results of operations. We are evaluating the impact on our results from adopting SFAS No. 123R, but we expect it to be comparable to the pro forma effects of applying the original SFAS No. 123 (see Stock-Based Compensation in Note 2 for further details).

In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary Assets, which eliminates an exception in APB Opinion No. 29 for nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS No. 153 will be effective for us for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. We are evaluating the impact from adopting SFAS No. 153, which is not expected to have an impact on our consolidated financial position, results of operations or cash flows.

Note 6. Operating Segments / Geographic Information

Since 2003, we have considered our operations to consist of one segment. The development of the one segment approach corresponded to the implementation of our refinement in strategic focus in late 2002, and represents management's view of our operations.

We operate on a worldwide basis with two locations in the United States and one location in the United Kingdom, which are categorized below as North America and Europe, respectively. Revenues are allocated where the work is performed and not based upon the location of the client or the study.

Back to Index

Geographic information is as follows (in thousands of dollars):

Three Months Ended March 31, 2004

| | North America | Europe | Total |
|--------------------------------------|--------------------------|---------------|--------------|
| License revenues | \$ 2,295 | \$ 158 | \$ 2,453 |
| Service revenues | 15,553 | 2,458 | 18,010 |
| Site support revenues | 4,539 | 1,089 | 5,629 |
| Net revenues from external customers | \$ 22,387 | \$ 3,705 | \$ 26,092 |
| Income from operations | \$ 11,270 | \$ 776 | \$ 12,046 |
| Long-lived assets | \$ 14,509 | \$ 4,010 | \$ 18,519 |
| Identifiable assets | \$ 99,763 | \$ 8,683 | \$ 108,446 |

Three Months Ended March 31, 2005

| | North America | Europe | Total |
|--------------------------------------|--------------------------|---------------|--------------|
| License revenues | \$ 1,021 | \$ 642 | \$ 1,663 |
| Service revenues | 12,261 | 3,641 | 15,902 |
| Site support revenues | 4,433 | 916 | 5,349 |
| Net revenues from external customers | \$ 17,715 | \$ 5,199 | \$ 22,914 |
| Income from operations | \$ 5,699 | \$ 1,184 | \$ 6,883 |
| Long-lived assets | \$ 16,129 | \$ 9,181 | \$ 25,310 |
| Identifiable assets | \$ 107,452 | \$ 10,687 | \$ 118,139 |

[Back to Index](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement for Forward-Looking Information

The following discussion and analysis should be read in conjunction with our financial statements and the related notes to the consolidated financial statements appearing elsewhere in this Form 10-Q. The following includes a number of forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995 that reflect our current views with respect to future events and financial performance. We use words such as anticipate, believe, expect, intend, and similar expressions to identify forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, competitive factors, technological development, and market demand. These and other risk factors have been further discussed in our Form 10-K for the year ended December 31, 2004. Such risks and uncertainties could cause actual results to differ materially from historical results or future predictions. Further information on potential factors that could affect our financial results can be found throughout this Form 10-Q and our other reports filed with the Securities and Exchange Commission.

Overview

We were founded in 1977 to provide Cardiac Safety services to evaluate the safety of new drugs. We provide technology and services that enable the pharmaceutical, biotechnology and medical device industries to collect, interpret and distribute cardiac safety and clinical data more efficiently. We are a market leader in providing centralized electrocardiographic services (Cardiac Safety services or EXPeRT® ECG services) and a leading provider of technology and services that streamline the clinical trials process by enabling our clients to evolve from traditional, paper-based methods to electronic processing using our Clinical Data Management products and services.

Our solutions improve the accuracy, timeliness and efficiency of trial set-up, data collection from sites worldwide, data interpretation and new drug, biologic and device application submission. We offer Cardiac Safety services, which are utilized by clinical trial sponsors and Clinical Research Organizations (CROs) during the conduct of clinical trials, including comprehensive Thorough QTc studies. Services may be provided through the Digital ECG Franchise program, which offers a unique approach designed to address the growing capacity demands for eRT's ECG services through partnerships with sponsors that desire dedicated resources within eRT to address specific levels of cardiac safety monitoring transactions. Additionally, we offer the licensing and, at the client's option, hosting of our proprietary Clinical Data Management software products and the provision of maintenance and consulting services in support of our proprietary Clinical Data Management software products. We offer the following products and services on a global basis:

EXPeRT®. EXPeRT® Cardiac Safety services provide intelligent, workflow-enabled cardiac safety data collection, interpretation and distribution of electrocardiographic (ECG) data and images, as well as analysis and cardiologist interpretation of ECGs performed on research subjects in connection with our clients' clinical trials. In addition, we establish rules for standardized, semi-automated and automated workflow management, allowing audit trail accounting and generating safety and operational metrics reports for sponsors and investigators. Also included in EXPeRT® Cardiac Safety services is FDA XML delivery which provides for the delivery of ECGs, encapsulated in the now approved FDA XML schema standard, to Cardiac Safety customers.

eRC. eResearch Community (eRC) is a central command and control portal that provides real-time information related to monitoring clinical trial activities, data quality and safety.

eDE. eData Entry (eDE) technology provides a comprehensive electronic data capture (EDC) system comprised of technology and consulting services formulated to deliver rapid time to benefit for electronic trial initiatives.

eResNet. The eResearch Network (eResNet) technology provides an integrated end-to-end clinical research solution that includes trials, data and safety management modules.

Back to Index

Project Assurance/Implementation Assurance. We provide a full spectrum of consulting services for all of our products that augment the study management and implementation efforts of clients in support of their clinical research requirements.

Our license revenues consist of license fees for perpetual licenses and monthly and annual license sales. Our services revenues consist of Cardiac Safety services, technology consulting and training services and software maintenance services. Our site support revenue consists of cardiac safety equipment rentals and sales along with related supplies and freight.

We recognize software revenues in accordance with Statement of Position 97-2, Software Revenue Recognition, as amended by Statement of Position 98-9. Accordingly, we recognize up-front license fee revenues under the residual method when a formal agreement exists, delivery of the software and related documentation has occurred, collectability is probable and the license fee is fixed or determinable. We recognize monthly and annual license fee revenues over the term of the arrangement. Hosting service fees are recognized evenly over the term of service. Cardiac Safety services revenues consist of fee for service revenues and are recognized as the services are performed. Site support revenues are recognized at the time of sale or over the rental period. We recognize revenues from software maintenance contracts on a straight-line basis over the term of the maintenance contract, which is typically twelve months. We provide consulting and training services on a time and materials basis and recognize revenues as we perform the services.

For arrangements with multiple deliverables where the fair value of each element is known, the revenue is allocated to each component based on the relative fair values of each element. For arrangements with multiple deliverables where the fair value of the delivered element is not known, revenue is allocated to each component of the arrangement using the residual method provided that the fair value of all undelivered elements is known. Fair values for undelivered elements are based primarily upon stated renewal rates for future products or services.

Cost of licenses consists primarily of applications service provider (ASP) fees for those clients that choose hosting, the cost of producing compact disks and related documentation and royalties paid to third parties in connection with their contributions to our product development. Cost of services includes the cost of Cardiac Safety services and the cost of technology consulting, training and maintenance services. Cost of Cardiac Safety services consists primarily of direct costs related to our centralized Cardiac Safety services and includes wages, depreciation and other direct operating costs. Cost of technology consulting, training and maintenance services consists primarily of wages, fees paid to outside consultants and other direct operating costs related to our consulting and client support functions. Cost of site support consists primarily of wages, cardiac safety equipment rent and depreciation, related supplies, cost of equipment sold, shipping expenses and other direct operating costs. Selling and marketing expenses consist primarily of wages and commissions paid to sales personnel, travel expenses and advertising and promotional expenditures. General and administrative expenses consist primarily of wages and direct costs for our finance, administrative, corporate information technology and executive management functions, in addition to professional service fees and corporate insurance. Research and development expenses consist primarily of wages paid to our product development staff, costs paid to outside consultants and direct costs associated with the development of our technology products.

We conduct our operations through offices in the United States and the United Kingdom (UK). Our international net revenues represented approximately 14% and 23% of total net revenues for the three months ended March 31, 2004 and 2005, respectively. The increase in the percentage of UK revenues is due to our management assigning more studies to the UK location. Revenues are allocated to locations where the work is performed and not based upon the location of the client or the study.

Back to Index

Results of Operations

Recent Developments

On April 27, 2005, we announced that our Board of Directors consented to the acquisition by Blum Capital Partners, L.P. (Blum Capital) or its affiliates of shares of our common stock which would result in Blum Capital becoming an interested stockholder within the meaning of Section 203 of the Delaware General Corporation Law (the "GCL"). The purpose of the Board's approval was to render the limitations set forth in Section 203(a) of the GCL inapplicable to Blum Capital. The approval of the Board was conditioned upon Blum Capital agreeing that, without the Board's approval, Blum Capital will not acquire beneficial ownership of 20% or more of our outstanding common stock.

In addition, the Board increased the number of directors from eight to nine and appointed John H. Park, CFA, to fill the vacancy created by the increase. Although Mr. Park's term of office will not expire until the 2008 Annual Meeting of Stockholders, the Board will submit Mr. Park's Board appointment to our stockholders for their ratification at the 2006 annual meeting and Mr. Park has agreed to resign if the stockholders do not ratify his appointment. Mr. Park is a Partner of Blum Capital.

On May 3, 2005, we announced that our Board of Directors authorized the purchase of up to an additional 10 million shares of our common stock, which extends the previously announced stock buy-back program to authorize the repurchase of a total of 12.5 million shares. The buy-back authorization allows us to make purchases from time to time on the open market at prevailing prices or in privately negotiated transactions. Our management will make the purchase decisions based upon market conditions and other considerations.

Executive Overview

As we discussed in our press release issued on March 10, 2005 and reiterated in our conference call regarding first quarter results on April 27, 2005, there continues to be significant uncertainty in the clinical research and drug development industry, due in part to evolving regulatory guidance. In our Form 10-K for the fiscal year ended December 31, 2004, see *Risks Related to Our Business---Extensive governmental regulation of the clinical trial process could require costly modifications to our products, adversely affect prospective clients' willingness to use our products and could increase competition and reduce our market share.* We believe that this uncertainty continues to delay new contract signings and extend the time for initiation of new studies. Although we believe that further clarification of this regulatory guidance will be provided in the second or third quarter of 2005 and that the continued uncertainty that we believe has temporarily impacted our industry may be alleviated, our results of operations may continue to be adversely affected if this clarification is delayed or does not adequately address the uncertainty in the industry.

Regulatory bodies, such as the United States Food and Drug Administration (FDA) and the International Conference on Harmonization (ICH), provide guidance on the clinical trial process. This guidance can have a significant influence on the decisions made by our clients and potential clients regarding the use of our services. For example, in the June 2004 ICH release, E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (Step 3), it was suggested that semi-automated processing of electrocardiograms may be found acceptable in certain instances. Semi-automated processing uses software algorithm placed measurements that are later adjudicated by a cardiac specialist or physician. We have historically been a leader in the industry in manual processing and we now also provide semi-automated processing with the same service level commitments to our customers as we have with our manual processing. Our manual processing includes manually performed measurements using our on screen, high resolution caliper placement system which are later interpreted by a cardiologist.

Back to Index

The following table presents certain financial data as a percentage of total net revenues:

| | <u>Three Months Ended March 31,</u> | |
|----------------------------|-------------------------------------|--------------|
| | <u>2004</u> | <u>2005</u> |
| Net revenues: | | |
| Licenses | 9.4% | 7.3% |
| Services | 69.0 | 69.4 |
| Site support | 21.6 | 23.3 |
| | <u>100.0</u> | <u>100.0</u> |
| Costs of revenues: | | |
| Cost of licenses | 0.5 | 0.6 |
| Cost of services | 22.9 | 28.3 |
| Site support | 9.1 | 13.9 |
| | <u>32.5</u> | <u>42.8</u> |
| Total costs of revenues | 32.5 | 42.8 |
| | <u>67.5</u> | <u>57.2</u> |
| Gross margin | 67.5 | 57.2 |
| Operating expenses: | | |
| Selling and marketing | 9.4 | 10.2 |
| General and administrative | 8.2 | 12.7 |
| Research and development | 3.7 | 4.3 |
| | <u>21.3</u> | <u>27.2</u> |
| Total operating expenses | 21.3 | 27.2 |
| Operating income | 46.2 | 30.0 |
| Other income (expense) net | 0.4 | 0.0 |
| | <u>46.6</u> | <u>30.0</u> |
| Income before income taxes | 46.6 | 30.0 |
| Income tax provision | 18.7 | 12.2 |
| | <u>27.9%</u> | <u>17.8%</u> |
| Net income | 27.9% | 17.8% |

[Back to Index](#)**Three Months Ended March 31, 2005 Compared to Three Months Ended March 31, 2004.**

The following table presents statements of operations with product line detail (in thousands):

| | Three Months Ended March 31, | | | |
|---|------------------------------|-----------------|---------------------|----------------|
| | 2004 | 2005 | Increase (Decrease) | |
| Licenses: | | | | |
| Net revenues | \$ 2,453 | \$ 1,663 | \$ (790) | (32.2%) |
| Costs of revenues | 122 | 133 | 11 | 9.0% |
| Gross margin | \$ 2,331 | \$ 1,530 | \$ (801) | (34.4%) |
| Services: | | | | |
| Cardiac Safety | | | | |
| Net revenues | \$ 16,021 | \$ 14,122 | \$ (1,899) | (11.9%) |
| Costs of revenues | 4,934 | 5,682 | 748 | 15.2% |
| Gross margin | \$ 11,087 | \$ 8,440 | \$ (2,647) | (23.9%) |
| Technology consulting and training | | | | |
| Net revenues | \$ 845 | \$ 594 | \$ (251) | (29.7%) |
| Costs of revenues | 759 | 514 | (245) | (32.3%) |
| Gross margin | \$ 86 | \$ 80 | \$ (6) | (7.0%) |
| Software maintenance | | | | |
| Net revenues | \$ 1,144 | \$ 1,186 | \$ 42 | 3.7% |
| Costs of revenues | 292 | 294 | 2 | 0.7% |
| Gross margin | \$ 852 | \$ 892 | \$ 40 | 4.7% |
| Total services | | | | |
| Net revenues | \$ 18,010 | \$ 15,902 | \$ (2,108) | (11.7%) |
| Costs of revenues | 5,985 | 6,490 | 505 | 8.4% |
| Gross margin | \$ 12,025 | \$ 9,412 | \$ (2,613) | (21.7%) |
| Site support: | | | | |
| Net revenues | \$ 5,629 | \$ 5,349 | \$ (280) | (5.0%) |
| Costs of revenues | 2,363 | 3,183 | 820 | 34.7% |
| Gross margin | \$ 3,266 | \$ 2,166 | \$ (1,100) | (33.7%) |
| Total: | | | | |
| Net revenues | \$ 26,092 | \$ 22,914 | \$ (3,178) | (12.2%) |
| Costs of revenues | 8,470 | 9,806 | 1,336 | 15.8% |
| Gross margin | 17,622 | 13,108 | (4,514) | (25.6%) |

Operating expenses:

Edgar Filing: ERESEARCHTECHNOLOGY INC /DE/ - Form 10-Q

| | | | | |
|-----------------------------|---------------|--------------|----------------|----------|
| Selling and marketing | 2,453 | 2,338 | (115) | (4.7%) |
| General and administrative | 2,150 | 2,896 | 746 | 34.7% |
| Research and development | 973 | 991 | 18 | 1.8% |
| | <u>5,576</u> | <u>6,225</u> | <u>649</u> | 11.6% |
| Operating income | 12,046 | 6,883 | (5,163) | (42.9%) |
| Other income (expense), net | 108 | (5) | (113) | (104.6%) |
| | <u>12,154</u> | <u>6,878</u> | <u>(5,276)</u> | (43.4%) |
| Income before income taxes | 12,154 | 6,878 | (5,276) | (43.4%) |
| Income tax provision | 4,886 | 2,806 | (2,080) | (42.6%) |
| | <u>7,268</u> | <u>4,072</u> | <u>(3,196)</u> | (44.0%) |
| Net income | \$ | \$ | \$ | |

Back to Index

The following table presents costs of revenues as a percentage of related net revenues and operating expenses as a percentage of total net revenues:

| | Three Months Ended March 31, | | |
|------------------------------------|-------------------------------------|-------------|--------------------------------|
| | 2004 | 2005 | Increase (Decrease) |
| Cost of licenses | 5.0% | 8.0% | 3.0% |
| Cost of services: | | | |
| Cardiac Safety | 30.8% | 40.2% | 9.4% |
| Technology consulting and training | 89.8% | 86.5% | (3.3%) |
| Software maintenance | 25.5% | 24.8% | (0.7%) |
| Total cost of services | 33.2% | 40.8% | 7.6% |
| Cost of site support | 42.0% | 59.5% | 17.5% |
| Total costs of revenues | 32.5% | 42.8% | 10.3% |
| Operating expenses: | | | |
| Selling and marketing | 9.4% | 10.2% | 0.8% |
| General and administrative | 8.2% | 12.7% | 4.5% |
| Research and development | 3.7% | 4.3% | 0.6% |

License revenues decreased primarily due to a decrease in the revenue from the sale of perpetual licenses primarily due to the fact that the average license revenue for each of the perpetual licenses sold in the first quarter of 2004 generated license revenues substantially in excess of the licenses sold in the first quarter of 2005. This is largely the result of the mix of licenses sold and the number of users for each license.

The decrease in Cardiac Safety service revenues was primarily due to a decrease in sales volume, including a decrease in transactions performed and a decrease in average revenue per transaction. The decrease in sales volume in the first quarter of 2005 was partially attributed to a decrease in comprehensive Thorough QTc studies. Thorough QTc studies are typically of large volume and of short duration, with ECGs performed over a two to six month period. As a result, revenues resulting from Thorough QTc studies are more difficult to predict. The decrease in average revenue per transaction is largely due to the impact of increased activity in franchise accounts which generally include lower fees per transaction than other studies. In addition, if drug sponsors shift towards semi-automated processing using software algorithm placed measurements in place of our manual high-resolution caliper placement system, more competitors may join our market, thus reducing pricing and our market share. The effect of such action may reduce our average revenue per transaction.

Technology consulting and training revenues decreased primarily due to a reduction in consulting on Clinical Data Management software products as there were several larger consulting engagements in the first quarter of 2004 with nothing of a comparable size in the first quarter of 2005.

Site support revenue decreased primarily due to a decrease in the revenue from the rental of cardiac safety equipment, which our clients use to perform cardiac safety procedures and related sales of supplies. The decrease in sales volume in the first quarter of 2005 was partially attributed to a decrease in comprehensive Thorough QTc studies. These decreases were partially offset by equipment sales of \$515,000 in the first quarter of 2005 while equipment sales in the first quarter of 2004 were immaterial. We have seen increased interest from clients in purchasing equipment during the latter part of 2004 and year-to-date 2005 which could indicate additional sales might occur in future periods.

The increase in the cost of Cardiac Safety services, both in absolute terms and as a percentage of Cardiac Safety service revenues, was primarily due to an increase in labor, depreciation and increased facilities and other costs associated with expanding capabilities to meet the past and expected growth in Cardiac Safety service revenues. Partially offsetting these increases is a reduction in amortization expense related to internal use software costs and a reduction in incentive bonuses due to higher targets set for the first quarter of 2005 that were not fully achieved. See [Liquidity and Capital Resources](#) for additional information related to internal use software. The increase in the cost of Cardiac Safety services as a percentage of Cardiac Safety service revenues was also due to the fact that some of the costs do not necessarily increase or decrease in direct relation with changes in revenue.

Back to Index

The decrease in the cost of technology consulting and training services, both in absolute terms and as a percentage of technology consulting and training service revenues, was primarily due to a reduction in third-party consulting costs which is partially attributable to the decrease in related revenue and a reduction in incentive bonuses due to higher targets set for the first quarter of 2005 that were unmet.

The increase in the cost of site support, both in absolute terms and as a percentage of site support revenues, was due primarily to an increase in rental and depreciation costs associated with cardiac safety rental equipment, cost of equipment sold in the first quarter of 2005 and other costs associated with expanding capabilities to meet the past and expected growth in site support activities, including the addition of new dedicated site support facilities in both the US and UK during 2004.

The decrease in selling and marketing expenses was primarily due to lower commissions that resulted from a decrease in commissionable revenue and the conversion of certain business development directors from incentive compensation primarily based upon commission to one primarily based upon bonus. In the first quarter of 2005, bonus targets generally exceeded actual performance, and resulted in lower incentive bonuses compared to the first quarter of 2004. The increase in selling and marketing expenses as a percentage of total net revenues was due to maintaining other selling and marketing expenditures despite the decrease in total net revenues.

The increase in general and administrative expenses, both in absolute terms and as a percentage of total net revenues, was due primarily to costs incurred in the first quarter of 2005 for consultants assisting with fiscal 2004 internal control work required by the Sarbanes-Oxley Act as well as increased audit and internal control attestation fees of our independent registered public accountants and higher labor costs due to new hires. These increases were partially offset by a reduction in incentive bonuses due to higher targets in the first quarter of 2005 that were not fully achieved. The increase in general and administrative expenses as a percentage of total net revenues was also due to the decrease in net revenues and the fact that general and administrative expenses do not necessarily increase or decrease with changes in revenues.

Other income (expense), net, consisted primarily of interest income realized from our cash, cash equivalents and short-term investments, net of interest expense related to capital lease obligations. In the first quarter of 2005, other income (expense), net also included an investment impairment charge of \$284,000 which was the result of continued negative market conditions affecting the carrying value of our investment in Essential Group, Inc. At March 31, 2005, the carrying value for Essential Group, Inc. was \$225,000. Exclusive of the investment impairment charge, other income, net increased \$171,000 primarily due to higher balances of cash, cash equivalents and short-term investments in the first quarter of 2005 as well as a shift to higher yielding money market investments and a decrease in interest expense related to capital leases in the first quarter of 2005.

Our effective tax rate was 40.2% and 40.8% for the three months ended March 31, 2004 and 2005, respectively. The first quarter of 2005 tax rate is comparable to the effective tax rate for the entire fiscal year 2004 which increased from the first quarter of 2004 primarily due to increased income before taxes with relatively static offsets such as tax credits for research and development. As income increased, the impact of these tax offsets has decreased as a percentage of income before income taxes, and as a result, the effective tax rate has increased.

Liquidity and Capital Resources

At March 31, 2005, we had \$38.9 million of cash and cash equivalents and \$31.9 million invested in short-term investments. We generally place our investments in money market funds, municipal securities, bonds of government sponsored agencies, certificates of deposit with fixed rates with maturities of less than one year, and A1P1 rated commercial bonds and paper.

For the three months ended March 31, 2005, our operations provided cash of \$5.0 million compared to \$13.4 million during the three months ended March 31, 2004. The change was primarily the result of a reduction in deferred revenues due to franchise activity exceeding franchise payments in the first quarter of 2005 compared to the first quarter of 2004 where deferred revenue increased as franchise payments exceeded franchise activity. The decrease in operating cash flow was also attributed to lower operating income and smaller income tax benefits related to stock options recognized during the three months ended March 31, 2005 compared to the three months ended March 31, 2004. This change was partially offset by a

Back to Index

much smaller increase in accounts receivable due to lower revenue and the impact of franchise study activity, which is largely prepaid.

For the three months ended March 31, 2005, our investing activities used cash of \$12.1 million compared to \$11.3 million during the three months ended March 31, 2004. The change was primarily the result of the net purchases of short-term investments, which totaled \$9.0 million for the three months ended March 31, 2005, compared to \$7.3 million for the three months ended March 31, 2004.

During the three months ended March 31, 2005, we capitalized \$3.1 million of property and equipment compared to \$4.0 million capitalized in the first quarter of 2004. The decrease was primarily the result of software purchased in the first quarter of 2004 used in the development of the upgrade to EXPeRT® as discussed below.

Included in property and equipment is internal use software associated with the development of a data and communications management services software product (EXPeRT®) used in connection with our centralized core cardiac safety electrocardiographic services. We capitalize certain internal use software costs in accordance with Statement of Position 98-1. The amortization is charged to the cost of Cardiac Safety services beginning at the time the software is ready for its intended use. The initial development costs of EXPeRT® were for the basic functionality required for this product. Additional development costs of EXPeRT® were incurred to develop new functionalities and enhancements. We started a new internal use software project to allow for semi-automated processing of ECGs in the second quarter of 2003 and further enhancements were begun in October 2004. We also began capitalizing costs associated with an upgrade to EXPeRT® beginning in the fourth quarter of 2003.

In mid-August of 2004, we revised our estimated timing for the completion of the upgrade to EXPeRT® to continue the development work through the fourth quarter of 2005 as opposed to the first quarter of 2005, as we previously had estimated. As this upgrade will replace many parts of the existing EXPeRT® product, we previously had accelerated the amortization of previously capitalized labor and consulting costs to fully amortize the associated costs of the existing EXPeRT® product by the end of the first quarter of 2005, which increased monthly amortization expense by \$76,000 beginning in the fourth quarter of 2003. Beginning in mid-August of 2004, we revised the amortization period for previously capitalized labor and consulting costs to fully amortize the associated costs of the existing EXPeRT® product by the end of the fourth quarter of 2005, which decreased monthly amortization expense by \$76,000 beginning in mid-August 2004. At the beginning of April 2005, we decided to extend the life of the existing EXPeRT® product to co-exist with the upgrade and will extend the depreciation period through August 2006 which coincides with our standard useful life for internal use software of four years. This will result in a decrease in monthly amortization expense of \$32,000 beginning in April 2005.

The following table presents the internal use software costs and related amortization as of March 31, 2005, with the exception of EXPeRT® which reflects the changes to be made in April 2005 as noted above (in thousands):

| | <u>Amortization Start Date</u> | <u>Labor and Consulting</u> | <u>Related Direct Costs of Materials</u> | <u>Total Capitalized Costs</u> | <u>Monthly Amortization</u> | <u>Accumulated Amortization</u> |
|---|------------------------------------|---------------------------------|--|--|---------------------------------|-------------------------------------|
| EXPeRT® | | | | | | |
| Initial costs | August 2002 | \$ 2,618 | \$ 1,413 | \$ 4,031 | \$ 54 | \$ 3,143 |
| Additional costs | April 2003 | 1,003 | 50 | 1,053 | 13 | 831 |
| Semi-automated ECG processing software | | | | | | |
| Initial costs | February 2004 | 449 | 361 | 810 | 17 | 237 |
| Enhancements | October 2004 | 380 | | 380 | 8 | 48 |
| Additional enhancements | May 2005 | 377 | | 377 | | |
| Upgrade to EXPeRT® | March 2006 (estimated) | 2,646 | 1,139 | 3,785 | | |
| Total | | \$ 7,473 | \$ 2,963 | \$ 10,436 | \$ 92 | \$ 4,259 |

Back to Index

For the three months ended March 31, 2005, our financing activities provided cash of \$226,000 compared to cash provided of \$706,000 for the three months ended March 31, 2004. The change was primarily the result of lower net proceeds from exercise of stock options in the first quarter of 2005 as compared to the first quarter of 2004.

We have a line of credit arrangement with Wachovia Bank, National Association totaling \$3.0 million. For the three months ended March 31, 2005, we had no outstanding borrowings under the line.

We expect that existing cash and cash equivalents, short-term investments, cash flows from operations and available borrowings under our line of credit will be sufficient to meet our foreseeable cash needs for at least the next year. However, there may be acquisition and other growth opportunities that require additional external financing and we may from time to time seek to obtain additional funds from the public or private issuances of equity or debt securities. There can be no assurance that any such acquisitions will occur or that such financings will be available or available on terms acceptable to us.

As noted in Recent Developments, the stock buy-back program was recently extended by 10 million shares to a total of 12.5 million shares. The purchase of a majority of the shares authorized could require us to use a significant portion of our cash, cash equivalents and short-term investments and could also require us to seek additional external financing. The stock buy-back authorization allows us, but does not require us to purchase the authorized shares.

Inflation

We believe the effects of inflation and changing prices generally do not have a material adverse effect on our results of operations or financial condition.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our primary financial market risks include fluctuations in interest rates and currency exchange rates.

Interest Rate Risk

We generally place our investments in money market funds, municipal securities, bonds of government sponsored agencies, certificates of deposit with fixed rates with maturities of less than one year, and A1P1 rated commercial bonds and paper. We actively manage our portfolio of cash equivalents and short-term investments, but in order to ensure liquidity, will only invest in instruments with high credit quality where a secondary market exists. We have not held and do not hold any derivatives related to our interest rate exposure. Due to the average maturity and conservative nature of our investment portfolio, a sudden change in interest rates would not have a material effect on the value of the portfolio. Management estimates that had the average yield of our investments decreased by 100 basis points, our interest income for the three months ended March 31, 2005 would have decreased by approximately \$175,000. This estimate assumes that the decrease occurred on the first day of 2005 and reduced the yield of each investment by 100 basis points. The impact on our future interest income of future changes in investment yields will depend largely on the gross amount of our cash, cash equivalents and short-term investments. See Liquidity and Capital Resources as part of Management's Discussion and Analysis of Financial Condition and Results of Operations.

Foreign Currency Risk

We operate on a global basis from locations in the United States and the United Kingdom. All international net revenues are billed and expenses incurred in either U.S. dollars or pounds sterling. As such, we face exposure to adverse movements in the exchange rate of the pound sterling. As the currency rate changes, translation of the income statement of our UK subsidiary from the local currency to U.S. dollars affects year-to-year comparability of operating results. We do not hedge translation risks because any cash flows from UK operations are generally reinvested in the UK.

Management estimates that a 10% change in the exchange rate of the pound sterling would have impacted the reported operating income for the three months ended March 31, 2005 by less than \$120,000.

[Back to Index](#)

Item 4. Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended, as of March 31, 2005. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by our Company (including our consolidated subsidiaries) in our periodic filings with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms. There has been no change in our internal control over financial reporting during the quarter ended March 31, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Back to Index

Part II. Other Information

Item 6. Exhibits

31.1 Certification of Chief Executive Officer.

31.2 Certification of Chief Financial Officer.

32.1 Statement of Chief Executive Officer Pursuant to Section 1350 of Title 18 of the United States Code.

32.2 Statement of Chief Financial Officer Pursuant to Section 1350 of Title 18 of the United States Code.

[Back to Index](#)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

eResearchTechnology, Inc.
(Registrant)

Date May 5, 2005

By:

Joseph A. Esposito

Joseph A. Esposito
President and Chief Executive Officer,
Director (Principal executive officer)

Date: May 5, 2005

By:

Bruce Johnson

Bruce Johnson
Senior Vice President and Chief Financial Officer
(Principal financial and accounting officer)

[Back to Index](#)

EXHIBIT INDEX

| Exhibit No. | Exhibit |
|--------------------|--|
| 31.1 | Certification of Chief Executive Officer. |
| 31.2 | Certification of Chief Financial Officer. |
| 32.1 | Statement of Chief Executive Officer Pursuant to Section 1350 of Title 18 of the United States Code. |
| 32.2 | Statement of Chief Financial Officer Pursuant to Section 1350 of Title 18 of the United States Code. |